LUCD Lucid Diagnostics Inc
- Stocks
- Healthcare
- NASDAQ: LUCD
Price (delayed)
$1.09
Market cap
$118.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$114.67M
Relative Growth:
Rel. Growth:
72
Relative Strength:
Rel. Strength:
58
Relative Valuation:
Rel. Valuation:
5
Relative Profitability:
Rel. Profitability:
3
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux,
Highlights
The EPS has increased by 16% year-on-year and by 13% since the previous quarter
LUCD's revenue is up by 15% year-on-year and by 4.5% since the previous quarter
Lucid Diagnostics's debt has surged by 94% YoY but it has decreased by 22% QoQ
The quick ratio has surged by 55% since the previous quarter but it has declined by 32% year-on-year
Lucid Diagnostics's equity has plunged by 51% YoY
Key stats
What are the main financial stats of LUCD
Market
Valuations
Earnings
Shares outstanding
108.48M
Market cap
$118.24M
Enterprise value
$114.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
15
Price to sales (P/S)
24.75
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.3
Revenue
$4.36M
Gross profit
-$2.58M
Operating income
-$47.94M
Net income
-$55.26M
EBIT
-$55.24M
EBITDA
-$54.36M
Free cash flow
-$43.44M
Per share
Balance sheet
Liquidity
EPS
-$1.03
EPS diluted
-$1.03
Free cash flow per share
-$0.44
Book value per share
$0.07
Revenue per share
$0.04
TBVPS
$0.39
Total assets
$38.67M
Total liabilities
$30.81M
Debt
$27.55M
Equity
$7.86M
Working capital
$4.41M
Debt to equity
3.5
Current ratio
1.15
Quick ratio
1.07
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
-1,246.7%
Gross margin
-59.2%
Net margin
-1,267.4%
Operating margin
-1,099.5%
Return on assets
-217.4%
Return on equity
-1,908.5%
Return on invested capital
-994.8%
Return on capital employed
-597.5%
Return on sales
-1,266.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUCD stock price
How has the Lucid Diagnostics stock price performed over time
Intraday
-1.8%
1 week
-12.8%
1 month
4.81%
1 year
15.34%
YTD
33.14%
QTD
7.92%
Financial performance
How have Lucid Diagnostics's revenue and profit performed over time
Revenue
$4.36M
Gross profit
-$2.58M
Operating income
-$47.94M
Net income
-$55.26M
Gross margin
-59.2%
Net margin
-1,267.4%
The company's net income fell by 18% YoY but it rose by 11% QoQ
LUCD's revenue is up by 15% year-on-year and by 4.5% since the previous quarter
Lucid Diagnostics's net margin has increased by 14% QoQ but it has decreased by 3.2% YoY
The gross margin is up by 12% since the previous quarter and by 12% year-on-year
Price vs fundamentals
How does LUCD's price correlate with its fundamentals
Growth
What is Lucid Diagnostics's growth rate over time
Valuation
What is Lucid Diagnostics stock price valuation
P/E
N/A
P/B
15
P/S
24.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.3
The EPS has increased by 16% year-on-year and by 13% since the previous quarter
Lucid Diagnostics's equity has plunged by 51% YoY
The price to sales (P/S) is 41% higher than the last 4 quarters average of 17.5
LUCD's revenue is up by 15% year-on-year and by 4.5% since the previous quarter
Efficiency
How efficient is Lucid Diagnostics business performance
The return on equity has dropped by 148% year-on-year and by 50% since the previous quarter
The ROA has decreased by 27% YoY but it has increased by 8% from the previous quarter
The return on sales has increased by 14% since the previous quarter but it has declined by 3.6% year-on-year
Lucid Diagnostics's return on invested capital has increased by 5% QoQ
Dividends
What is LUCD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUCD.
Financial health
How did Lucid Diagnostics financials performed over time
Lucid Diagnostics's total assets is 26% higher than its total liabilities
The company's total liabilities has surged by 70% YoY but it fell by 19% QoQ
The quick ratio has surged by 55% since the previous quarter but it has declined by 32% year-on-year
The debt to equity has soared by 153% QoQ
Lucid Diagnostics's debt has surged by 94% YoY but it has decreased by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.